Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

BACKGROUND & AIMS Alcohol is the leading cause of cirrhosis and liver-related mortality, but we lack serum markers to detect compensated disease. We compared the accuracy of the Enhanced Liver Fibrosis test (ELF), the FibroTest, liver stiffness measurements (made by transient elastography and 2-dimensional shear-wave elastography), and 6 indirect marker tests in detection of advanced liver fibrosis (Kleiner stage ≥F3). METHODS We performed a prospective study of 10 liver fibrosis markers (patented and not), all performed on the same day. Patients were recruited from primary centers (municipal alcohol rehabilitation, n = 128; 6% with advanced fibrosis) and secondary health care centers (hospital outpatient clinics, n = 161; 36% with advanced fibrosis) in the Region of Southern Denmark from 2013 through 2016. Biopsy-verified fibrosis stage was used as the reference standard. The primary aim was to validate ELF in detection of advanced fibrosis in patients with alcoholic liver disease recruited from primary and secondary health care centers, using the literature-based cutoff value of 10.5. Secondary aims were to assess the diagnostic accuracy of ELF for significant fibrosis and cirrhosis and to determine whether combinations of fibrosis markers increase diagnostic yield. RESULTS The ELF identified patients with advanced liver fibrosis with an area under the receiver operating characteristic curve (AUROC) of 0.92 (95% confidence interval 0.89-0.96); findings did not differ significantly between patients from primary vs secondary care (P = .917). ELF more accurately identified patients with advanced liver fibrosis than indirect marker tests, but ELF and FibroTest had comparable diagnostic accuracies (AUROC of FibroTest, 0.90) (P = .209 for comparison with ELF). Results from the ELF and FibroTest did not differ significantly from those of liver stiffness measurement in intention-to-diagnose analyses (AUROC for transient elastography, 0.90), but did differ in the per-protocol analysis (AUROC for transient elastography, 0.97) (P = .521 and .004 for comparison with ELF). Adding a serum marker to transient elastography analysis did not increase accuracy. For patients in primary care, ELF values below 10.5 and FibroTest values below 0.58 had negative predictive values for advanced liver fibrosis of 98% and 94%, respectively. CONCLUSION In a prospective, direct comparison of tests, ELF and FibroTest identified advanced liver fibrosis in alcoholic patients from primary and secondary care with high diagnostic accuracy (AUROC values of 0.90 or higher using biopsy as reference). Advanced fibrosis can be ruled out in primary health care patients based on an ELF value below 10.5 or a FibroTest value below 0.58.

[1]  G. Perlemuter,et al.  Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[2]  D. Schuppan,et al.  Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values? , 2017, Hepatology.

[3]  Ioan Sporea,et al.  EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version) , 2017, Ultraschall in der Medizin - European Journal of Ultrasound.

[4]  T. Gerds,et al.  Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: A nationwide prospective cohort study , 2017, Hepatology.

[5]  C. Day,et al.  Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance , 2016, British Medical Journal.

[6]  M. Thiele,et al.  Feasibility of transient elastography versus real-time two-dimensional shear wave elastography in difficult-to-scan patients , 2016, Scandinavian journal of gastroenterology.

[7]  M. Thiele,et al.  Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease , 2016, Ultraschall in der Medizin - European Journal of Ultrasound.

[8]  L. Henry,et al.  Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. , 2016, Gastroenterology.

[9]  S. Mueller,et al.  Inflammation‐adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[10]  A. Walker,et al.  Causes of Death in People with Liver Cirrhosis in England Compared with the General Population: A Population-Based Cohort Study , 2015, The American Journal of Gastroenterology.

[11]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[12]  G. Cooke,et al.  The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa , 2015, Gut.

[13]  P. O’Rourke,et al.  ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[14]  T. Card,et al.  Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography , 2015, BMJ Open.

[15]  V. de Lédinghen,et al.  An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. , 2015, Journal of hepatology.

[16]  A. Burroughs,et al.  Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. , 2015, The Cochrane database of systematic reviews.

[17]  D. Leeming,et al.  Review article: the efficacy of biomarkers in chronic fibroproliferative diseases – early diagnosis and prognosis, with liver fibrosis as an exemplar , 2014, Alimentary pharmacology & therapeutics.

[18]  Korbinian Brand,et al.  The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. , 2013, Journal of hepatology.

[19]  Ngoc Wasson,et al.  Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection , 2013, Annals of Internal Medicine.

[20]  Peter Schlattmann,et al.  Use of 3×2 tables with an intention to diagnose approach to assess clinical performance of diagnostic tests: meta-analytical evaluation of coronary CT angiography studies , 2012, BMJ : British Medical Journal.

[21]  R. Bataller,et al.  Alcoholic liver disease: pathogenesis and new therapeutic targets. , 2011, Gastroenterology.

[22]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[23]  Y. Ngo,et al.  Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease , 2009, Hepatology.

[24]  M. Ziol,et al.  Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. , 2008, Journal of hepatology.

[25]  I. Guha,et al.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers , 2007, Hepatology.

[26]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[27]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[28]  D. Schuppan,et al.  Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.

[29]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[30]  D. Valla,et al.  Five‐year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence , 2003, Liver international : official journal of the International Association for the Study of the Liver.

[31]  Llorenç Quintó,et al.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.

[32]  T. Poynard,et al.  Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study , 2001, The Lancet.

[33]  M. Tsutsumi,et al.  Characteristics of serum hyaluronate concentrations in patients with alcoholic liver disease. , 1997, Alcoholism, clinical and experimental research.

[34]  P. Bedossa,et al.  Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus , 1997, Journal of viral hepatitis.

[35]  O. Aasland,et al.  Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. , 1993, Addiction.

[36]  J. Hoofnagle,et al.  Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. , 1988, Gastroenterology.

[37]  D. Mayfield,et al.  The CAGE questionnaire: validation of a new alcoholism screening instrument. , 1974, The American journal of psychiatry.

[38]  V. de Lédinghen,et al.  EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version) , 2017, Ultraschall in der Medizin - European Journal of Ultrasound.

[39]  S. Liangpunsakul,et al.  Early detection of alcoholic liver disease - are we a step closer? , 2017 .

[40]  J. Trebicka,et al.  Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis. , 2016, Gastroenterology.

[41]  D. Crabb,et al.  Early Detection of Alcoholic Liver Disease: Are We a Step Closer? , 2016, Gastroenterology.

[42]  R. de Franchis.  Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. , 2015, Journal of hepatology.

[43]  Kathleen F. Kerr,et al.  Net reclassification indices for evaluating risk prediction instruments: a critical review. , 2014, Epidemiology.

[44]  J. Rehm,et al.  Alcohol and Mortality , 2014, Alcohol Research : Current Reviews.

[45]  W. Rosenberg,et al.  Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. , 2009, Gastroenterology.